AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$ABT

MCCOY JOHN A. JR. sold $3K of ABT

MCCOY JOHN A. JR. (VICE PRESIDENT AND CONTROLLER) sold 27 shares of ABBOTT LABORATORIES (ABT) at $109.54 on 2026-09-02.

Original reporting
SEC EDGAR · MCCOY JOHN A. JR.
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ABT
Neutral
high confidence
Mentioned
$ABT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABTNeutralLow
01

Why it matters

The transaction is a routine sale with minimal market relevance.

02

Market read

Low relevance; no expected price movement.

03

What to watch

Potential upcoming earnings or corporate actions not disclosed.

Relevance 3/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filing for Abbott Laboratories insider transaction.

Company-level read

Ticker impact

$ABTNeutralHigh confidence
Context

Form 4 shows VP John McCoy sold 27 shares for $2,958, reducing his stake to 24,549 shares.

Expected impact

No material impact expected.

Evidence & confidence

Sale size is trivial relative to market cap and insider ownership.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider sells can signal concerns, but evidence is insufficient.

Key entities

  • company
    Abbott Laboratories

    US healthcare company (ticker ABT).

  • person
    John A. McCoy Jr.

    Vice President and Controller, insider.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABT insider trading history →

Related articles

SEP 21
$ABTMedAI 8/10

NC reaches settlement with Abbott over contaminated baby formula that led to 2022 shortage

North Carolina settled with Abbott Laboratories for $384M over contaminated baby formula, part of a broader agreement with 39 states and the federal government. Abbott, which produces over 40% of U.S. formula, was accused of selling unsafe products and concealing test results. The recall caused a 2022 shortage. North Carolina's share is $216K, earmarked for Medicaid and nutrition programs.

wral.com2 min
SEP 21
$ABTHighAI 8/10

Abbott Laboratories To Pay $385M Over Allegations Of Tainted Infant Formula

Abbott Laboratories will pay $385M to resolve allegations of tainted infant formula. The settlement includes $348.7M to the federal government and $35.5M to state Medicaid programs. California's share is over $15M. The allegations span 2018-2022, involving production conditions that risked microorganism contamination. Abbott recalled several formula brands in 2022, leading to a nationwide shortage.

patch.com2 min
SEP 20
$ABTLowAI 8/10

Sunday Edition: Sodium

Abbott Laboratories agreed to pay $384.9M to settle a DOJ case over a 2022 infant formula outbreak. The settlement doesn't determine liability. Pending lawsuits remain. No specific company was named in an E. coli and Salmonella outbreak linked to seed supplier Everything Sprouts LLC. Italy's hepatitis A outbreak affected 130 people, possibly from bivalve mollusks. UK small businesses show good food safety practices but low awareness of food crime.

foodsafetynews.com4 min
SEP 20
$ABTLow

State settles infant formula contamination lawsuit, more Health Headlines

Colorado will receive nearly $2 million from Abbott Laboratories as part of a $348 million settlement over allegations of misrepresenting the safety of its infant formula, with additional $35.5 million to be split among states. The lawsuit claimed Abbott failed to maintain safety standards and disclose contamination test results. The funds will be returned to Colorado's Medicaid program.

gjsentinel.com2 min
SEP 19
$ABTMedAI 8/10

Abbott Laboratories Pays 384 Million In Baby Formula Safety Settlement

Abbott Laboratories (ABT) will pay $384 million to settle a lawsuit alleging it failed to maintain safety standards in its baby formula manufacturing facilities from 2018 to 2022, according to New York Attorney General Letitia James. The settlement includes $348 million to the federal government and $35 million to a coalition of states, with New York receiving $9.3 million. The lawsuit claimed Abbott's practices put products at risk of contamination and misled safety inspectors.

wpdh.com2 min